Nirsevimab for Respiratory Syncytial Virus (MUSIC Trial)

"This clinical research is seeking participants between infancy and two years of age."

"This research project, which is expected to last 360 days past the dose administration period, aims to observe Treatment emergent serious adverse events (TESAEs). Additional objectives include measuring Area under the concentration-time curve [AUC], Apparent clearance, and terminal-phase half-life [t1/2] as well as Maximum observed concentration [Cmax]. All of these parameters help evaluate nirsevimab's PK."

"Nirsevimab, a drug developed by MedImmune LLC and studied in 3013 patients since 2019, is currently the subject of 3 active trials spanning 34 countries and 103 cities. Subsequent to completing Phase 3 clinical approval 4 years ago, numerous other studies have been concluded."

"Nirsevimab's safety was estimated at a 2 on our scale due to the lack of efficacy-related data surrounding this Phase 2 trial."

"At the present moment, this medical trial is not open to potential participants. Initially posted on August 19th 2020, it was most recently updated on November 10th 2022. For those looking for other clinical trials, there are currently 33 studies recruiting patients with infections and 3 separate nirsevimab trials searching for enrollments."

"At present, Nirsevimab is being studied in three clinical trials; two of which are currently at Phase 3. Despite the primary research sites being located in Gent and Virginia, there exist 366 other locations to participate in the study."

"Currently, this trial is running out of 9 distinct medical facilities, including those in Syracuse, Chicago and Fort Worth. For individuals who want to take part but don't wish to incur a lot of travel costs or time commitments, it might be best to select the closest site."

"This study is recruiting 100 infants and toddlers aged 0-2, affected by Respiratory Syncytial Virus. To qualify for the clinical trial, these individuals must meet certain criteria including being diagnosed with a combined immunodeficiency or Human Immunodeficiency Virus infection, receiving immunosuppressive chemotherapy, systemic high-dose corticosteroid therapy (over 0.5mg/kg every other day), or another form of immunosuppressive treatment; as well as having their parent(s)/legal representative(s) agree to the consent process and follow up visits which will span one year after they receive nirse"

"The trial is no longer accepting applicants. Originally posted on August 19th 2020 and last updated November 10 2022, other prospective studies that involve infections such as respiratory syncytial virus (RSV) or Nirsevimab have 33 locations actively recruiting participants."